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SUMMARY 
Mutations and polymorphisms in the gene encoding factor H (CFH) have been 
associated with atypical Hemolytic Uremic Syndrome (aHUS), Dense Deposit Disease 
(DDD) and Age-related Macular Degeneration (AMD). Experimental evidence supports 
that many of these CFH genetic variations disrupt the regulatory role of factor H (FH), 
sustaining the concept that dysregulation of complement is a unifying pathogenic 
feature of these disorders. Evidence of a causal relationship with the disease is, 
however, not available for all CFH genetic variations found in patients, which is a 
potential cause of misinterpretations with important consequences for the patients and 
their relatives. I890 and L1007 are two of such CFH genetic variations. They have 
repeatedly been reported associated with aHUS and are also found in DDD and AMD 
patients. Here we report an extensive genetic and functional analysis of these CFH 
variants. Our results indicate that I890 and L1007 segregate together as part of a distinct 
and relatively infrequent CFH haplotype in Caucasians. Extensive analysis of the 
purified S890/V1007 (control) and I890/L1007 (disease-associated) FH protein variants 
failed to provide evidence that these amino acid substitutions have functional 
implications. These data, the presence of the I890 and L1007 variants in healthy 
individuals and their high frequency in Sub-Saharan African and African American 
populations strongly suggest that I890 and L1007 are FH rare polymorphisms unrelated 
with disease. 
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INTRODUCTION 
Complement factor H (FH) is the main regulator of the alternative pathway (AP) 
of the complement system. FH exerts this regulatory activity in three different ways: it 
binds to C3b, competing with factor B (FB) in the assembly of the AP C3-
proconvertase complex (C3bB); it accelerates the decay of the AP C3-convertase 
(C3bBb); and acts as cofactor of factor I (FI) in the proteolytic inactivation of C3b 1-3. 
FH regulates complement activation both in fluid phase and on cellular surfaces 4-6, 
preserving complement homeostasis and preventing uncontrolled C3b deposition and 
host tissue damage. 
FH is a relative abundant plasma protein that is secreted as a single-chain 
glycoprotein of 155 KD composed of 20 homologous domains of 60 amino acids 7, 
named short consensus repeats (SCR). FH concentration in plasma is highly variable, 
ranging from 116 to 562 µg/ml 8. Different interaction sites for C3b and polyanions 
have been identified along the 20 SCR of FH. The SCR 1-4 region is the unique C3b 
binding site capable to act as cofactor for FI in the cleavage of C3b and to accelerate the 
decay of AP C3-convertase 9.  Similarly, the C3b and polyanion binding site at SCR 19-
20 determines the ability of FH to bind C3b deposited on the cell surface, being this 
region of FH essential for self-pathogen discrimination 10, 11. 
Mutations and polymorphisms in the CFH gene are associated with atypical 
hemolytic uremic syndrome (aHUS), dense deposit disease (DDD), and age-related 
macular degeneration (AMD) (reviewed in 12). The available data support the 
hypothesis that AP dysregulation is a unifying pathogenic feature of these diverse 
conditions. They also illustrate a remarkable genotype-phenotype correlation in which 
distinct genetic variations at CFH specifically predispose to aHUS, AMD or DDD. In 
fact, the functional characterization of these disease-specific CFH genetic variations is 
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being instrumental to understand the molecular basis underlying each of these 
pathologies. 
In aHUS, a thrombotic microangiopathy characterized by thrombocytopenia, 
haemolytic anemia and acute renal failure, and where endothelial cell injury appears to 
be the primary pathogenic event, the most prevalent genetic alterations in the CFH gene 
are missense mutations that alter the C3b- and polyanion-binding site at the C-terminus 
of FH. These mutations rarely result in hypocomplementemia or decreased FH plasma 
levels 13-16. Functional studies have demonstrated that these aHUS-associated FH 
molecules present normal regulatory activity in plasma but a limited capacity to protect 
cells from complement lysis 17-20. This functional alteration is clearly distinct from the 
lack of complement regulation in plasma, leading to complete C3 consumption and 
severe hypocomplementemia that characterizes DDD patients. 
DDD is a very rare form of glomerulonephritis with isolated C3 deposits 
characterized by the presence of dense deposits within the glomerular basement 
membrane (GBM) 21. DDD is associated with complement abnormalities that lead to 
persistent reduction of C3 serum levels and to intense deposition of degradation 
products of C3 in the GBM. Among the different factors associated with these 
complement abnormalities are mutations in the CFH gene. These CFH mutations result 
in truncations or amino acid substitutions that impair secretion of FH into circulation or 
that eliminate the complement regulatory activities located at the N-terminus of FH 22-24. 
Thus, CFH mutations that decrease FH in plasma, or eliminate its complement 
regulatory activity, lead to unrestricted activation of complement in plasma, causing 
damage to glomerular cells and deposition of complement products in the GBM. 
Age-related macular degeneration (AMD), the most common cause of blindness 
in the elderly in developed countries, is characterized by drusen, lipoproteinaceous 
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deposits localized between the retinal pigment epithelium (RPE) and Bruch´s 
membrane, that lead to an extensive atrophy of the RPE and overlaying photoreceptor 
cells (geographic atrophy, GA) or aberrant choroidal neovascularization (CNV) under 
the macular area. AMD and DDD share pathological similarities with accumulation of 
complement-containing debris within the eye and kidney respectively. Indeed, AMD-
like pathology is well-recognized in patients with DDD 25. The identification of CFH as 
a major susceptibility locus for AMD and the characterization of multiple genetic 
variants in the CFH genomic regions conferring risk or protection to AMD indicate that 
the complement system plays a significant role in AMD pathogenesis 26-30. However, 
CFH association data showed no overlapping between CFH at-risk polymorphisms for 
aHUS and AMD 20. 
The peculiar genotype-phenotype correlation between specific CFH genetic 
variations and a particular disease contrast with the situation of the CFH I890 and 
L1007 variations (in SCR 15 and SCR 17, respectively) that have been repeatedly 
reported associated with aHUS and are also found in DDD and AMD patients 29, 31-33. 
To characterize the functional consequences of these CFH genetic variations we have 
purified the different FH protein variants to homogeneity from the plasma of 
appropriate carriers and tested their capacity to bind to surface-bound C3b, analyzed 
their cofactor activity in the FI-mediated inactivation of fluid phase C3b and performed 
FH-dependent hemolytic assays. None of these assays showed functional alterations in 
the regulatory activity of the FH, which strongly suggest that they are rare FH 
polymorphisms without functional consequences. 
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RESULTS 
Sequencing analyses of the CFH gene in the aHUS (n=259) and DDD (n=19) 
Spanish cohorts identified four aHUS patients (H54, H97, H142 and H244) and one 
DDD patient (GN3) carrying two nucleotide changes (c.2669 G>T; S890I and c.3019 
G>T; V1007L) in heterozygosis. The same c.2669 G>T and c.3019 G>T nucleotide 
changes were also detected in heterozygosis in two out of 173 controls, an occurrence 
that is not significantly different to that found in patients. These Complement profiles 
and clinical data of the aHUS and DDD patients carrying the S890I and V1007L amino 
acid changes, as well as additional genetic alterations in other complement genes found 
in these patients are summarized in Table 1. 
Two aHUS pedigrees were available for segregation analysis. In both cases it 
was demonstrated that the patients inherited both nucleotide changes (c.2669 G>T and 
c.3019 G>T) from the same progenitor, illustrating that they were carried by the same 
CFH allele. Further analyses of several SNPs within the CFH gene demonstrated that in 
all carriers, these I890 and L1007 amino acid changes associated with the same CFH 
haplotype, suggesting a single evolutionary origin for the I890/L1007 CFH haplotypes 
identified in the aHUS, DDD and control individuals (Table 2). Interestingly, the 
I890/L1007 CFH haplotype carries the AMD and DDD risk polymorphism His402, 
which may have implications for its association with AMD and DDD. The I890/L1007 
CFH haplotype is probably old. This is supported by the existence of I890/L1007 CFH 
“recombinant” haplotypes like that of H97, affecting the promoter region of CFH or the 
genomic rearrangement that resulted in the generation of the CFH::CFHR1 hybrid gene 
in H142. 
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As indicated, the I890/L1007 CFH haplotype in H142 is remarkable because, in 
addition, it encodes a CFH::CFHR1 hybrid gene that resulted from a non-homologous 
recombination between the CFH and CFHR1 genes. Thus, the FH protein encoded by 
this CFH allele carries a total of four amino acid changes compared to a normal CFH 
allele: I890 and L1007 and another two (L1191 and A1197) characteristic of the exon 6 
of CFHR1 fused to the exon 23 of CFH in the CFH::CFHR1 hybrid gene (Table 2) 34. 
To purify the I890/L1007 FH variant from non-mutated FH in heterozygote 
carriers we used affinity chromatography with the MBI-7 anti-human FH monoclonal 
antibody 35. This antibody specifically recognizes the H402 variant of FH and was used 
to capture the FH allele carrying the I890 L1007 amino acid changes from the plasma of 
patients H54 and H142, who are FH Y402H heterozygotes. The eluted protein was 
further purified by gel filtration and concentrated free of contaminants. We followed the 
same protocol to purify the S890/V1007 FH allele from control FH Y402H 
heterozygote donors (Figure 1). After quantification by ELISA, the purified proteins, 
S890/V1007, I890/L1007 and I890/L1007/L1191/A1197, were tested functionally in a 
number of different assays. 
To test whether the I890/L1007 amino acid changes affect the cofactor activity 
for the FI-mediated proteolysis of C3b, S890/V1007 and I890/L1007 FH variants were 
mixed with C3b and incubated in the presence of FI at 37ºC. After densitometric 
analysis of coomassie stained gels, the ratio between α´chain/βchain of C3b was used to 
calculate the percentage of C3b cleavage. As illustrated, no differences in the cofactor 
activities between FH variants S890/V1007 and I890/L1007 (Figure 2A,B) or between 
S890/V1007 and I890/L1007/L1191/A1197 (Figure 2A,B,C) were appreciated, 
indicating that these amino acid substitutions do not have a significant effect on the 
cofactor activity of FH. As a control that our assays have appropriate sensitivity to 
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detect small functional alterations we have included in these experiments the V62 and 
I62 FH polymorphic variants previously, which shown to present slightly differences in 
their FI cofactor activities 36 (Figure 2D)  
To explore the effect of the I890/L1007 amino acid changes in the interaction 
with C3b we performed a C3b binding plate assay. Purified C3b was immobilized on 
microtiter plates and identical quantities of the I890/L1007 and S890/V1007 FH 
variants were added and allowed to interact for two hours at 37°C. FH bound to C3b 
was detected using the Ox24 monoclonal antibody. FH was quantified in parallel in the 
same ELISA experiment. Our results show that the binding to C3b of the purified FH 
protein I890/L1007 was undistinguishable from that of the control FH S890/V1007 
(Figure 3A). These results indicate that the amino acid changes in the SCR 15 and 17 do 
not alter the capacity of FH to bind C3b. We also used in these experiments the V62 and 
I62 FH polymorphic variants as it has also been shown previously that they present 
slight differences in their C3b-binding capacity 36 (Figure 3B). 
To investigate the potential effect of the I890 and L1007 amino acid changes 
in the regulatory activity of FH on cell surfaces, the S890/V1007 and I890/L1007 FH 
variants were tested in a FH-dependent hemolytic assay developed in our laboratory. In 
these assays a human serum carrying a well-characterized CFH mutation that alters the 
C-terminus of FH 18, was reconstituted with identical amounts of the S890/V1007, 
I890/L1007 or I890/L1007/L1191/A1197 FH variants and incubated with sheep 
erythrocytes in the presence of 7 mM Mg2+ and EGTA. Lysis of erythrocytes in this 
assay inversely correlates with the capacity of FH to regulate the alternative pathway on 
the cellular surface. Our results indicate that the I890/L1007/L1191/A1197 FH variant 
presents decreased inhibition of the erythrocyte lysis compared with the native non-
mutated variant of FH (figure 4B). This reduced capacity to regulate the alternative 
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pathway on the cellular surface was expected because this FH variant is also the product 
of a CFH::CFHR1 hybrid gen 34. In contrast, the FH variant from H54 showed no 
difference with the FH control and demonstrated to act efficiently in the protection 
against erythrocyte lysis. These data, again, indicates that the S890I and V1007L amino 
acid substitutions are not altering the capacity of FH to regulate the complement AP on 
the cellular surface. 
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DISCUSSION 
Mutation screening of complement genes in aHUS, DDD and AMD has become 
a laboratory routine. Identification of mutations helps diagnosis and provides useful 
information to anticipate the evolution of the disease in the patients and their response 
to treatments, conditioning clinical decisions. For example, among aHUS patients, those 
carrying CFH mutations have the worse prognosis and poorest renal transplantation 
outcomes, although they associate with good responses to plasma treatment. In addition, 
identification of mutations and polymorphisms associated with increased risk to these 
pathologies also influence the genetic counselling provided to patients and their 
relatives. It is therefore critical to obtain evidence supporting that the disease-associated 
mutations identified in these screenings have a causal relationship with the pathology. 
Here we have studied two FH amino acid substitutions, I890 and L1007, lacking these 
functional information that have repeatedly been found among Spanish aHUS and DDD 
patients and that have also been reported associated with aHUS in other Caucasian 
cohorts 31-33. In addition, S890I and V1007L were described as rare polymorphisms 
associated with AMD 29. 
The peculiar concurrence of both S890I and V1007L amino acid substitutions in 
all these cases is explained by the segregation analysis performed here in two aHUS 
pedigrees that revealed that these two amino acid changes segregate together with a 
unique CFH haplotype characterized by a specific combination of SNPs (Table 2). The 
high allelic frequency of the S890I and V1007L polymorphisms in Sub-Saharan African 
(0,267; 0,317) and African American (0,455; 0,591) populations (rs515299 and 
rs534399, respectively), suggest that this CFH haplotype has an African origin and was 
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introduced in Caucasians some time ago. In support of this conclusion, one of the 
patients in our cohort carrying this haplotype (H244) has a Sub-Saharan African origin. 
Carriers of the I890/L1007 CFH haplotype present normal FH levels in plasma 
with a contribution of the I890/L1007 FH allele of approximately 50% (Table 1). These 
data illustrate that these amino acid substitutions do not influence the 
expression/secretion of FH. To characterize the potential consequences of the S890I and 
V1007L substitutions in the functional activities of FH we performed three different 
functional assays using purified FH proteins. We tested the capacity of the I890/L1007 
FH variant to bind to surface-bound C3b, analyzed its cofactor activity in the FI-
mediated inactivation of fluid phase C3b and performed a FH-dependent hemolytic 
assay to determine its capacity to regulate the alternative pathway on cellular surfaces. 
None of these assays showed functional alterations in the regulatory activity of FH. This 
failure to detect functional alterations caused by the S890I and V1007L substitutions is 
not a consequence of a lack of sensitivity of our assays. They clearly revealed the subtle 
functional differences caused by the FH Val62Ile polymorphism or by the modification 
of the C-terminal region of FH that occurs in the CFH::CFHR1 hybrid gene 34, 36. We, 
therefore, concluded that the FH S890I and V1007L variants are most likely CFH 
polymorphisms without functional consequences. Furthermore, recent structural data 
have shown that SCR15 and SCR17, including these variations, are not implicated in 
the interaction between FH and C3b (Morgan et al. 2011). 
Carriers of the I890/L1007 CFH haplotype in the Spanish aHUS cohort present 
other well-characterized mutations and/or polymorphisms in complement genes that 
may help to explain the development of the disease in these individuals. Thus, patient 
H54 carries in homozygosis the aHUS-conferring risk allele MCPggaac 37; Patient H97 
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also carries in homozygosis the MCPggaac allele and, in addition, the mutation C86Y in 
the FI gene which produces a partial deficiency of FI in plasma (Table 1); and in patient 
H142, the I890/L1007 CFH haplotype also carries a CFH::CFHR1 hybrid gene, which 
produces a FH protein with reduced capacity to regulate the alternative pathway on 
cellular surfaces (Figure 4B) 34. Similarly, patient GN3 is positive for C3 nephritic 
factor (C3Nef). Lastly, an increased frequency of the I890/L1007 CFH haplotype in 
DDD and AMD should be expected because this CFH haplotype also carries the CFH 
H402 allele (rs1061170), a very strong risk factor for both AMD and DDD 20, 26. 
In conclusion, we failed to provide evidence supporting a causal relationship of 
I890/L1007 with aHUS. The lack of functional consequences of the CFH S890I and 
V1007L amino acid substitutions, their presence in healthy individuals and their very 
high frequency in Sub-Saharan African and African American populations strongly 
suggest that S890I and V1007L are rare FH polymorphisms unrelated with the disease.  
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MATERIALS AND METHODS 
Complement analysis, mutation screening and genotyping. 
C3 and C4 concentrations were determined by nephelometry (Immage®, 
Beckman Coulter) and FH plasma concentration was quantified by a specific sandwich 
ELISA method using polyclonal and monoclonal antibodies developed in house that 
does not cross react with the CFHRs proteins.  No C3Nef was measured in serum 
plasma by standard procedures 38. Patients and healthy volunteers were screened for 
mutations and polymorphisms in the CFH, MCP, CFI, CFB, C3 and THBD genes by 
automatic DNA sequencing of PCR amplified fragments. Genomic DNA was prepared 
from peripheral blood cells according to standard procedures. Each exon was amplified 
from genomic DNA by using specific primers derived from the 5’ and 3’ intronic 
sequences as described 15, 39-41. Automatic sequencing was performed in an ABI 3730 
sequencer using a dye terminator cycle sequencing kit (Applied Biosystems, Foster 
City, CA). Copy number variations in the CFHR1-R3 genes were analyzed by MLPA as 
described 42. The studies described herein received IRB approval (Comision de 
Bioetica, Consejo Superior de Investigaciones Científicas and CEIC, Hospital 
Universitario La Paz, Madrid, Spain). Patients and their relatives gave their informed 
consent.  
Proteins 
FH allele carrying the mutations I890 and L1007 was isolated from fresh plasma 
of aHUS patient H54 and a relative of the aHUS patient H142. We used a CNBr-
activated sepharose 4B (GE healthcare) column coupled with the monoclonal antibody 
MBI-7 that exclusively recognizes the FH H402 protein variant 35. Fractions containing 
  14
FH were collected, concentrated and applied to a gel-filtration column (Superose 6, GE 
Healthcare). Fractions containing the FH were pooled and purity of final preparations 
was confirmed in SDS-PAGE coomassie stained gels (Figure 1). C3 was purified by 
affinity chromatography and gel filtration as described previously 43. C3b was generated 
by limited digestion with trypsin and re-purified by gel filtration as described above. 
C3b was obtained without any detectable contaminants or aggregates. Factor I was 
purchased from Comptech (Tyler, TX). Concentration of sample proteins was assessed 
using absorbance at 280 nm and molarities were calculated using an extinction 
coefficient for CFH of 1.95 35 and for C3 of 0.98 (Protean Software, DNAStar).  
Cofactor activity for FI-mediated proteolysis of fluid phase C3b 
The fluid-phase cofactor activity of FH was determined in a C3b proteolysis 
assay using purified proteins. In brief, C3b, FH and FI were mixed in 10 mM Hepes pH 
7.5, 150 mM NaCl, 0.02% Tween 20 at final concentrations of 50 μg/ml, 4 μg/ml and 
2.5 μg/ml, respectively. Mixtures were incubated at 37ºC during 10 minutes. In another 
set of assays, samples were collected at 2.5, 5, 7.5 and 10 minutes of incubation. The 
reactions were stopped by the addition of 3μl of SDS sample buffer (2% SDS, 62.5 mM 
Tris, 10% Glycerol, 0.75% Bromophenol Blue). Samples were analyzed in 10% SDS-
PAGE under reducing conditions. Gels were stained with Coomassie brilliant blue R-
250 (BioRad) and proteolysis of C3b determined by measuring the cleavage of the 
α’chain using a GS-800 calibrated densitometer (BioRad) and the MultiGauge software 
package (Fujifilm). The C3b βchain was used as an internal control to normalize the 
amount of protein added between samples. Percentage of cleavage was determined by 
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the ratio between α´chain/βchain of C3b and setting as 0% of proteolysis by using a 
control FH in the absence of FI. 
 
 
ELISA C3b–binding assay 
The binding of FH variants to surface-bound C3b was determined by ELISA 
method. 96-well polystyrene microtiter plates were coated with C3b (2.5 μg/ml) in 
coupling buffer (0.1 M NaHCO3 pH 9.5) overnight at 4ºC. The plate was blocked with 
washing buffer (20 mM Tris, 150 mM NaCl and 0.1% Tween 20) with 1% Bovine 
Serum Albumin for 1 hour at room temperature (RT). After washing, serial dilutions of 
FH variants (starting dilution was 2.5μg/ml) were added and incubated with surface-
bound C3b for 2 hours at 37ºC. After washing, the plate was incubated with anti-FH 
monoclonal antibody Ox24 for 1 hour at RT, and then with a secondary antibody 
coupled with horseradish peroxidase (DAKO). Colour reaction was developed with o-
phenylene-diamine (DAKO) and absorbance measured at 492 nm. FH preparations used 
in the ligand assay were quantified in duplicate in the same ELISA plate using 
immobilised polyclonal anti-FH antibody to capture FH followed by the Ox24 and 
secondary antibodies to measure the amount of FH. Concentrations of FH were 
calculated from curves obtained using purified standard samples. 
Factor H-dependent hemolytic assay 
The capacity of FH to regulate the activity of the AP on cellular surfaces was 
assessed with a hemolytic assay using sheep erythrocytes and a serum carrying a well-
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characterized CFH mutation, FH-W1183L 18. In brief, 1x107 sheep erythrocytes in AP 
buffer: VBS (2.5 mM barbital, 1.5 mM sodium barbital, 144 mM NaCl, pH 7.4) with 7 
mM MgCl2 and 10 mM EGTA, were incubated with 10% FH-W1183L serum in AP 
buffer and increasing amounts of the different FH variants for 30 minutes at 37 °C. The 
reaction was stopped by adding VBS 20 mM EDTA. After centrifugation, supernatants 
were read at 414 nm. FH variants I890/L1007 and I890/L1007/L1191/A1197 were 
compared to the same control FH variant, S890/V1007, in two independent assays. 
S∆FH without added FH was taken as 100% of lysis and serum diluted in AP buffer 
plus 20 mM EDTA were used as blank for spontaneous lysis. 
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TABLE 1. Clinical and complement data of patients carrying the CFH I890 and L1007 genetic variants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 aHUS DDD 
 H54(1) H97 H142(2) H244(3) GN3(4) 
Age of onset (years) 51 41 3.5 1 5.5 
C3 (700-1400 µg/ml) 59 123 94,3 135 135 
C4 (140-470 µg/ml) 7 24,5 24,2 31,5 31,5 
Total FH (116-562 µg/ml) 127,4 256,8 150 316 161,8 
% FHI890-L1007* 46% 47% 56% - - 
FI (75-115%)** 99% 52% 104% 80% 103% 
Additional mutations none CFI C86Y CFH::CFHR1 hybrid gene none none 
Del CFHR1-CFHR3 none none het none none 
Autoantibodies none none none none C3Nef 
Renal status (outcome)*** Deceased ESRD ESRD MRI MRI 
Transplantation (recurrences) none Yes (no) Yes (no) none none 
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(1) Male patient who was diagnosed of post-transplant HUS (microangiopathic hemolytic anemia with schistocytes, and renal 
failure) associated with Tacrolimus and Cyclosporin threatment. He died one month later from pneumonia caused by 
Acynetobacter and Aspergillus.  
(2) After almost 4 years of haemodialysis, this male patient received a cadaver kidney transplant on September 2010. He was treated 
with eculizumab (Soliris®) before transplantation and every 15 days afterwards, following the protocol recommended by 
Alexion Pharmaceuticals. He is actually in good condition. 
(3) This is male child from Nigeria. He developed HUS after diarrhoea and a respiratory infection. He was under peritoneal dialysis 
and recovered partial renal function. No recurrences. Actually present moderate renal insufficiency 
(4) Diagnosis of DDD in this patient was established on the basis of renal biopsy (light microscopy, immunofluorescence and 
electron microscopy) performed at presentation of the disease. It was observed moderate mesangial hipercellularity and 
increased mesangial matrix without double-contour in the capillary walls. Immunofluorescence showed intense isolated 
granular C3 staining  in the capillary walls and in the mesangium as nodular ring forms, negative for immunoglobulins or 
other complement proteins. EM revealed abundant electrondense ribbon-like deposits within the GBM and local electrondense 
deposits in the mesangium. The presentation was a nephritic syndrome with microhematuria and without proteinuria. He 
showed persistence hypocomplementemia C3 (8 mg/dl) and four months after was C3NeF positive. This situation was 
maintained for 12 years. In 1992, at age 20 years old, he presented proteinuria 5.75 g/day; Serum Creatinine: 1,0 ; Creatinine 
Clearance: 147ml/min  and was remained C3Nef positive. He was treated with Prednisone. By 2007, after 33 years of 
evolution, the C3Nef titters were only detected as traces, with normalization of C3 levels and with an almost complete 
remission of the proteinuria after combined ACEI and ARB therapy. He presented ocular manifestations of AMD (drusen) at 
  28 
age 33. The patient actually presents a moderate renal insufficiency (Creatinine: 1,9 ; Creatinine Clearance: 65 ml/min ) and 
proteinuria 1,2 g/day.  
* In FH His402Tyr heterozygotes, levels of expression of the FHI890-L1007 alelle were determined by ELISA using anti FH 
402His specific antibodies35.  
**  Factor I levels are referred to a reference pool of sera. 
***  ESRD, end stage renal disease; MRI, moderate renal insufficiency. 
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. 
TABLE 2. CFH haplotypes carrying the FH I890 and L1007 amino acid substitutions. 
 
 
Promoter 
-232 C>T 
V62I 
c.184 G>A 
Y402H 
c.1204 T>C 
Q672Q 
c.2016 A>G
E936D 
c.2808 G>T 
S890I 
c.2669 G>T 
V1007L 
c.3019 G>T 
S1191 
c.3645 C 
V1197 
c.3663 T 
N1 C G C A G T T C T 
N2 C G C A G T T C T 
H54 C G C A G T T C T 
H244 C G C A G T T C T 
GN3 C G C A G T T C T 
H97 C A C A G T T C T 
H142 C G C A G T T C T 
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FIGURE LEGENDS 
 
Figure 1. SDS-PAGE coomassie-stained gel of the purified FH variants.  
The S890/V1007, I890/L1007 or I890/L1007/L1191/A1197 FH variants were purified 
from the plasma of a healthy individual and the aHUS patients H54 and H142, as 
described in Materials and Methods. 
 
Figure 2. Cofactor activity of FH variants in the proteolysis of fluid phase C3b. 
C3b and FI were incubated with equal amounts of either S890/V1007, I890/L1007 or 
I890/L1007/L1191/A1197 FH variants for 10 minutes at 37ºC and the reaction was 
stopped by the addition of SDS sample buffer. Samples were analyzed by SDS-PAGE 
under reducing conditions and gels were Coomassie-stained (a). A densitometric 
analysis of C3b proteolysis from triplicates of these experiments is shown in (b). A 
time-course analysis of C3b proteolysis is shown in (c). Fluid phase cofactor activity 
was measured be examining C3b cleavage at 2.5, 5, 7.5 and 10 minutes reaction for 
both control S890/V1007 (filled triangles) and I890/L1007/L1191/A1197 (open 
triangles) FH variants. Percentage of cofactor activity was determined by the ratio of 
C3b cleaved,  α´chain/βchain, and normalized to 0% proteolysis of control samples. 
Inset panel shows the double reciprocal plot of the S890/V1007 (open circles) and 
I890/L1007/L1191/A1197 (filled circles) of the cofactor activity curves. Multiple linear 
regression analysis showed no significant differences between the slopes for 
S890/V1007 and I890/L1007/L1191/A1197 cofactor activities. The sensitivity of our 
assay was demonstrated by including in the experiment a S890/V1007 FH carrying the 
I62 polymorphism (open circles). 
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Figure 3. Capacity of the FH variants to bind to C3b. 
The interaction between serial dilutions of purified FH with C3b deposited in 96-well 
plates is expressed as percentage of the amount of S890/V1007 FH variant bound to 
C3b at a concentration of 2.5 μg/ml. Means ± S.D. of three independent experiments are 
shown for I890/L1007 (open triangles), two samples of the S890/V1007 FH variant 
(filled triangles and filled circles) and for a S890/V1007 FH carrying the I62 
polymorphism (open circles). This last one sample illustrate the sensitivity of our assay. 
 
Figure 4. Inhibition of the lysis of sheep erythrocytes by the FH variants. 
A volume of serum from a control patient carrying a well-characterized mutation in 
CFH giving 100% lysis when added to sheep erythrocytes was mixed with different 
amounts of the purified FH variants. The lysis observed is shown as percentage of the 
lysis in the absence of added FH and was plotted against added FH. Means ± S.D. of 
three independent experiments are shown for S890/V1007 (open circles) and 
I890/L1007 (filled circles) (a) and for S890/V1007 (open circles) and 
I890/L1007/L1191/A1197 (filled circles) (b). Statistical differences as follows: *: 
p<0,05; **: p<0,01; ***: p<0,001. 
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